Small Molecule Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$466M

Range: $247M - $675M

Total Deal Value

$2.4B

Range: $1.5B - $3.4B

Royalty Rate

13.1% - 21.9%

Tiered up to 25.9%

Dev Milestones

$393M

Range: $252M - $536M

Model Your Deal

Market Analysis

Small Molecule therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 small molecule asset in immunology & autoimmune is $466M, with total deal values reaching $2.4B. Development milestones average $393M, while regulatory milestones contribute $688M.

The immunology & autoimmune small molecule landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for small molecule immunology & autoimmune deals range from 13.1% to 21.9% at the base tier, with tiered escalation reaching 17.1%-25.9% on blockbuster sales. Commercial milestones averaging $884M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a small molecule immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 small molecule licensing deals in immunology & autoimmune average $466M in upfront payments, with a range of $247M to $675M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for small molecule immunology & autoimmune transactions?

The median total deal value for Phase 2 small molecule assets in immunology & autoimmune is $2.4B, ranging from $1.5B to $3.4B. This includes development milestones ($393M), regulatory milestones ($688M), and commercial milestones ($884M).

What royalty rates are standard for small molecule deals in immunology & autoimmune?

Base royalty rates for small molecule immunology & autoimmune transactions range from 13.1% to 21.9%, with tiered escalations reaching 17.1%-25.9% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in small molecule immunology & autoimmune deals?

Small Molecule immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($393M) make up the largest share, followed by commercial milestones ($884M) and regulatory milestones ($688M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Small Molecule Deal Benchmarks in Immunology & Autoimmune

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Monoclonal Antibody in Immunology & Autoimmune

Bispecific Antibody in Immunology & Autoimmune

Small Molecule in Oncology

Small Molecule in Neurology

Ready to Calculate Your Deal Terms?